Nieder J, Claus P, Augustin W
Department of Gynaecology and Obstetrics, Otto-von-Guericke-University, Magdeburg, Germany.
Prostaglandins. 1995 May;49(5):311-8. doi: 10.1016/0090-6980(95)00052-c.
Current therapeutical concepts for prophylactic treatment of preeclampsia are based on the hypothesis that this pathological state is mainly due to a functional imbalance between vascular prostacyclin (PGI2) and thromboxane A2 (TXA2) biosynthesis. The influence of Trapidil on PGI2 and TXA2 formation was studied by in vitro perfusion of human umbilical veins by measuring the production of the metabolites 6-keto-PGF1 alpha and TXB2, respectively, in the perfusates using Enzyme-Immunoassay. The basal production of 6-keto-PGF1 alpha was 90.6 pg/mL/cm of vessel wall, whereas TXB2 formation attained a rate of 7.5 pg/mL/cm. The addition of Trapidil to the perfusate resulted in a significant stimulation of PGI2 production but apparently does not exhibit any effect on TXB2 generation. These data support the suggestion that Trapidil may act by increasing the ratio of PGI2/TXA2 in favor of the antiaggregatory/vasodilatory PGI2.
目前子痫前期预防性治疗的治疗理念基于这样一种假设，即这种病理状态主要是由于血管前列环素（PGI2）和血栓素A2（TXA2）生物合成之间的功能失衡所致。通过使用酶免疫测定法分别测量灌注液中代谢产物6-酮-PGF1α和TXB2的生成，对人脐静脉进行体外灌注，研究了曲匹地尔对PGI2和TXA2形成的影响。6-酮-PGF1α的基础生成量为90.6 pg/mL/cm血管壁，而TXB2的生成速率达到7.5 pg/mL/cm。向灌注液中添加曲匹地尔可显著刺激PGI2的生成，但显然对TXB2的生成没有任何影响。这些数据支持了曲匹地尔可能通过增加PGI2/TXA2的比例来发挥作用，从而有利于具有抗聚集/血管舒张作用的PGI2这一观点。
